Before a number is chosen, a prescriber settles whether tirzepatide fits the person at all. Indication, thyroid and endocrine history, current diabetes medications, pregnancy status, and prior incretin experience come first. Only then does the labeled entry point apply, and that entry point is 2.5 mg weekly for four weeks, with 5 mg as the step after it.
The indication question comes before the dose question
Mounjaro carries one approved indication: improving glycemic control in adults and pediatric patients aged 10 and older who have type 2 diabetes, used with diet and exercise. It is not the weight-management product. Tirzepatide for weight reduction and long-term maintenance is marketed as Zepbound, which also carries an indication for moderate to severe obstructive sleep apnea in adults with obesity.
Sorting this out early prevents a familiar sequence in which someone is measured against a benchmark the prescription was never written for. Current standards of care for type 2 diabetes treat agent selection as a function of cardiovascular and kidney status, hypoglycemia risk, weight, cost, and access, so the choice of tirzepatide over another class is itself a considered decision rather than a default.
The histories that end the conversation
Two contraindications appear on the label. A personal or family history of medullary thyroid carcinoma rules the drug out, as does multiple endocrine neoplasia syndrome type 2, both tied to a boxed warning built on thyroid C-cell tumors seen in rats whose relevance to humans remains unknown. Known serious hypersensitivity to tirzepatide or to any excipient in the product is the other.
The family history item depends entirely on what the patient can report. No test in the intake substitutes for it, which is why an assessment that never asks the question has skipped the one screen capable of stopping everything else.
Other findings reshape the plan without ending it. Severe gastroparesis makes the drug not recommended. A history of pancreatitis, existing gallbladder disease, diabetic retinopathy requiring monitoring, reduced kidney function, and pregnancy or plans to conceive all belong in the record before the first injection.
Why the entry point is fixed rather than individualized
People often expect a starting amount scaled to body size or to how high their blood sugar runs. Tirzepatide is not prescribed that way. The label sets one opening dosage for everyone and states directly that it is for treatment initiation and not intended for glycemic control.
The reason is that the first four weeks are testing gastrointestinal tolerance rather than treating anything. Tolerance does not scale with weight or with baseline A1C in any way that would give a prescriber something to individualize against. A larger person with a higher A1C is no more likely to sail through the first month than anyone else.
The fixed entry point is also visible in how providers describe the drug publicly. LillyDirect routes patients to the branded pen, while direct-to-consumer names such as Ro, Henry Meds, and HealthRX publish their own starting-dose explainers, with the HealthRX Mounjaro page stating the same 2.5 mg opening step. Where a provider’s public page disagrees with the label on that first number, the page is the thing to distrust.
What a request to begin at 5 mg is usually about
| The reason given | What the record supports |
|---|---|
| The first step does nothing, so it is wasted | Correct that it is not for glycemic control, incorrect that it is inert; it establishes tolerance |
| Previous GLP-1 use means tolerance is already built | Prior exposure is relevant history a prescriber weighs, not a labeled reason to skip a step |
| Higher body weight should mean a higher opening amount | The label sets no weight-based entry point for either tirzepatide product |
| The supply is limited, so time should not be wasted | A supply problem is a supply problem; it does not change what the label directs |
| A friend started higher without trouble | Individual reports say nothing about the pooled rates, which rise with dose |
| Results are not arriving fast enough | Early absence of effect is what the labeling anticipates during initiation |
None of these is unreasonable as a question. All of them are questions for the prescriber holding the chart, because the decision turns on the record rather than the reasoning.
Medication review is the step most often skipped
Tirzepatide alone rarely causes hypoglycemia. Combined with insulin or an insulin secretagogue it can, sometimes severely, and the labeled response is to consider reducing the other agent. Diabetes standards of care treat that review as part of starting any new glucose-lowering therapy, and it belongs in the intake rather than in a phone call after an episode.
Delayed gastric emptying also affects oral medications taken alongside, and the label attaches specific advice about oral contraception around initiation and each later increase. An intake that collects a medication list and never acts on it has produced paperwork rather than screening.
What the access route changes
A practice that already holds the chart starts from the history. LillyDirect connects patients to prescribers and dispenses the branded product. Direct-to-consumer services including Ro, Hims & Hers, LifeMD, Found, and FormBlends run their own intake, and the depth varies enough that it is worth asking the provider behind it which clinician reviews the file, what is actually screened for, and whether the same person handles the follow-up. A thin intake is recognizable once described: height, weight, a short checklist, instant approval, and no follow-up question about anything reported.
Compounded tirzepatide changes the numbers, not the screening
Compounded tirzepatide is not FDA-approved, and the agency has published specific concerns about unapproved GLP-1 products sold for weight loss. No reviewed label fixes a concentration or an escalation path, and strengths differ between compounding pharmacies, so a starting approach for a compounded preparation comes from the prescriber and pharmacy involved and cannot be read off the branded label.
Every contraindication above still applies in full. Those belong to the molecule and the patient rather than to the supply route.
Frequently asked questions
Does a higher A1C justify a higher opening amount?
No. The labeled entry point is the same regardless of baseline glycemic control, because the first four weeks assess tolerance rather than treat blood sugar. A high A1C affects how closely the response is watched and how quickly later steps are considered, not where the sequence begins.
What single history item most often stops the assessment?
Medullary thyroid carcinoma in the patient or a first-degree relative, or multiple endocrine neoplasia syndrome type 2. Both are labeled contraindications attached to the boxed warning, and both rest on family information no laboratory test can supply on the patient’s behalf.
Does previous experience with another GLP-1 change the starting approach?
It is genuine history and a prescriber will want it, including how the earlier drug was tolerated and why it stopped. Whether it changes anything is a judgment made case by case with the record available, and the approved sequence remains what the label describes.
Is a video visit enough for a first tirzepatide prescription?
It can be, if the history taken is real. What matters is whether contraindications, current diabetes medications, gastrointestinal history, and prior incretin exposure were asked about and acted on, not whether the encounter happened in an exam room or on a screen.
